Clinical Trial

Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

Study acronym: CONCORD
Recruiting
View on ClinicalTrials.gov →
Summary
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
Protocol Amendment History 4 changes
notable Trial sites expanded: 22 -> 26 locations 2026-07-11
notable Trial sites expanded: 18 -> 22 locations 2026-06-12
notable Primary completion pushed: 2028-06-30 -> 2028-11-30 2026-06-12
minor Completion pushed: 2028-06-30 -> 2028-11-30 2026-06-12
Trial Details
NCT Number NCT07052578
Lead Sponsor AstraZeneca
Conditions Prostate Cancer
Enrollment 400 participants
Start Date 2025-06-30
Primary Completion 2028-11-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-10